Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFFITOPE PD01A boost in Parkinson's disease
NCT02216188Phase 1Completed
- Sponsor
- AFFiRiS
- Start
- Aug 2014
- Primary completion
- Aug 2015
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AFFITOPE PD03A in Parkinson's disease (PD) (3 arms), sponsored by AFFiRiS. Primary endpoint: Tolerability at 6 months. Started Aug 2014; status: completed.
02
Drugs
AFFITOPE PD03A
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02216188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02216188.